Ruxolitinib (INC424 INCB18424 trade names Jakafi and Jakavi by Incyte Pharmaceuticals and Novartis) is a drug for the treatment of intermediate or high-risk myelofibrosis a type of bone marrow cancer. It is also being investigated for the treatment of other types of cancer (such as lymphomas and pancreatic cancer) for polycythemia vera and for plaque psoriasis.
This page contains content from the copyrighted Wikipedia article "Ruxolitinib"; that content is used under the GNU Free Documentation License (GFDL). You may redistribute it, verbatim or modified, providing that you comply with the terms of the GFDL.
